Third, investigating potential therapeutic targets remains crucial for chemoresistance of CRC [29]; the HR gene mutations as the second most prevalent ones in CRC patients, and their carrier’s demonstrated resistance to first-line chemotherapy, for which targeted therapy such as PARP inhibition might be alternative therapeutic strategy. The gene discussed is HR; the disease is colorectal carcinoma.